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Introduction
Breast cancer is a heterogeneous disease arising from
multiple genetic changes in oncogenes and tumour sup-
pressor genes with pivotal roles in the homeostatic control
of mammary epithelial cell proliferation, differentiation and
death. Aberrations in the expression and function of these
genes lead to clonal expansion with subsequent acquisi-
tion of invasive and metastatic phenotypes.
An increasing number of genes have been implicated in
the evolution of breast cancer, and this list is expected to
expand with the development of new genomics tools.
Studies to date have relied on correlations between gene
mutation, gene expression and breast cancer phenotype
to identify candidate genes, with demonstration of function
dependent on mechanistic studies in diverse experimental
systems. One powerful model system is the genetically
modified mouse where several genes induce mammary
carcinoma when expressed alone or in combination.
In a major recent advance, the laboratory of Piotr Sicinski
has combined transgenic and targeted gene deletion
approaches to address the requirement for the cell cycle
oncoprotein, cyclin D1, in the induction of mammary carci-
noma [1]. These novel data demonstrate that cyclin D1 is
essential for the development of mammary cancers
induced by c-neu and v-Ha-ras, but not those induced by
c-myc or Wnt-1. This is the first genetic evidence of an
absolute requirement for cyclin D1 in the formation of a
subset of mammary cancers, and supports an expanding
literature implicating this oncoprotein in the evolution of
human breast cancer.
Cyclin D1 is the product of the CCND1 gene and was
first implicated in tumourigenesis following localisation to
chromosome 11q13 [2], a region of the genome that is
commonly amplified in a range of human carcinomas
including breast cancer [3]. Cyclin D1 plays a pivotal role
in the regulation of progression from the G1 to the S
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phase of the cell cycle through the formation of active
enzyme complexes with cyclin-dependent kinases Cdk4
and Cdk6. These kinases phosphorylate substrates
including the retinoblastoma gene product, pRb, thus
relieving pRb’s inhibitory function on S phase entry [4].
This rate-limiting step in cell cycle progression is regulated
by a number of mechanisms including cyclin D1 abun-
dance [4]; consequently, dysregulation of cyclin D1 gene
expression or function is a probable contributor to loss of
normal cell cycle control during carcinogenesis.
Cyclin D1 in breast cancer
Chromosome 11q13 is amplified in ~15% of primary
breast cancers, and cyclin D1 is currently the most proba-
ble candidate oncogene at this locus [3]. The early
demonstration that cyclin D1 mRNA was overexpressed in
~45% of breast carcinomas identified cyclin D1 as one of
the most frequently overexpressed oncogenes in primary
breast cancer [5], an observation subsequently confirmed
by immunohistochemical studies [6,7].
There has been some debate as to when cyclin D1 over-
expression is first observed in the evolution of breast
cancer. In situ hybridisation studies suggest that cyclin
D1 overexpression occurs at the transition from in situ to
invasive cancer [8], while immunohistochemical studies
of preneoplastic lesions demonstrate that overexpression
was already apparent in hyperplasia and increased with
increasing malignancy [9]. If substantiated by further
studies, the latter data are compatible with a potential
role for cyclin D1 in the early phases of breast cancer
development.
Studies on primary breast cancers indicate that over-
expression is confined to specific phenotypes, implying
different roles in different subtypes of the disease. Lobular
carcinoma appears to universally overexpress cyclin D1
[10], while overexpression in ductal carcinoma is confined
almost exclusively to oestrogen receptor positive cases
[5]. A potential functional link between oestrogen receptor
positivity and cyclin D1 overexpression is supported by
evidence that cyclin D1 plays a major role in oestrogen-
induced mitogenesis in breast cancer cells [11].
Cyclin D1 in mammary gland development
and carcinogenesis
Mammary development is impaired in cyclin D1 null mice
such that, although the basic ductal structure forms nor-
mally at puberty, alveoli do not develop during pregnancy
and lactation does not occur [12,13]. This defect does not
appear to reflect a necessity for cyclin D1 per se, since
epithelium lacking both cyclin D1 and p27 can form a
normal mammary gland [14], as can epithelium in which
cyclin D1 has been replaced by cyclin E [15]. Instead, it
appears that the specific requirement is for timely epithe-
lial cell proliferation.
Overexpression of cyclin D1 in the virgin mammary gland
causes increased proliferation and precocious alveolar
development, mimicking early pregnancy [16]. These
mouse mammary tumour virus (MMTV)-cyclin D1 mice
eventually develop mammary adenocarcinomas, with a
mean age at onset of ~18 months [16]. This is a consider-
ably longer timeframe than those observed for MMTV-myc
mice (~11 months), MMTV-Ha-ras mice (~5.6 months) or
MMTV-neu (~3 months) mice [17,18]. While the onco-
genic capacity of these genes in mammary tissue is clear,
the long latencies of c-myc-induced and cyclin D1-
induced tumours in particular indicate that, on their own,
they are weak oncogenes and may require cooperating
oncogenes for efficient carcinogenesis. Indeed, almost
one-half of the tumours induced by tetracycline-regulated
c-Myc expression also acquired mutations in K-ras or N-
ras [19], complementing early data demonstrating that
tumour incidence in the presence of both MMTV-myc and
MMTV-Ha-ras was accelerated compared with either
oncogene alone [18].
Cooperation between oncogenes in
mammary carcinogenesis
The data outlined above focus attention on a critical ques-
tion: are there preferred pathways that cooperate with
cyclin D1 to promote mammary carcinogenesis? The pub-
lication of Yu et al. [1] addresses this issue and, impor-
tantly, indicates preferential cooperation with c-neu and
v-Ha-ras. These experiments provide further strong evi-
dence for a critical role for cyclin D1 in the development of
mammary cancer, but also raise additional questions
about the interaction between different oncogenes in a
cell-specific context. What is clearly apparent, and may
have been inferred from early studies in cyclin D1 null
mice, is that cyclin D1 plays a very specific role in the
normal mammary gland and mammary carcinogenesis. The
defect in mammary development in cyclin D1 null mice
occurs despite the presence of the often redundant D2
and D3 cyclins [1]. Similarly, MMTV-neu-induced and
MMTV-ras-induced tumourigenesis was not impaired in
cyclin D2 and D3 null mice, and cyclin E could substitute
for cyclin D1 in tumourigenesis as well as mammary devel-
opment [1]. This implies it is the tissue-specific regulation
and timing of cyclin D1 expression that is critical to these
processes. In support of this concept, increased expres-
sion of cyclin D1 but not cyclins D2 and D3 was observed
in MMTV-neu-induced and MMTV-ras-induced mammary
tumours, while MMTV-Wnt-1-induced and MMTV-myc-
induced tumours expressed both cyclins D1 and D2 [1].
The lack of dependence of c-myc-induced tumours of the
mammary gland on cyclin D1 is perhaps not surprising
given evidence that these two oncogenes act through
separate pathways to activate cyclin E–Cdk2 and cell
cycle progression in breast cancer cells [20]. Evidence
from other model systems that cyclin D2 is a Myc-inducedBreast Cancer Research    Vol 4 No 1 Sutherland and Musgrove
gene that contributes to cyclin E–Cdk2 activation through
sequestration of p27Kip1 into cyclin D2–cyclin-dependent
kinase complexes similarly supports the data presented by
Yu et al. It is noteworthy, however, that in the lymphoid
system there is strong cooperativity between cyclin D1
and c-myc in lymphomagenesis [21], again illustrating the
cell specificity of oncogene interactions in tumourigenesis.
The Wnt-1 oncogene has major effects on mammary gland
development and is a potent oncogene in mammary epithe-
lium. Wnt-1 induced precocious mammary gland develop-
ment in cyclin D1 null mice, indicating that it could replace
cyclin D1 function in both development and tumourigenesis
[1]. Such data do not support the view that Wnt signalling
through accumulation of β-catenin and, consequently,
increased cyclin D1 gene expression is a major pathway in
mammary epithelium, as has been proposed in other tissues
[22]. While this pathway is probably intact in the mammary
gland and breast cancer [23], the present data support a
role for Wnt-1 induction of cyclin D2 as a significant down-
stream effector in mammary epithelium.
Conclusions
Taken together, these data provide compelling evidence
for a requirement for appropriate regulation of cyclin D1
gene expression in the development of the mouse
mammary gland and the induction of tumours by c-neu
and v-Ha-ras. This appears to relate to the temporal
expression of the gene rather than its function since a
cyclin E knockin at the cyclin D1 locus can restore normal
function. In light of the induction of cyclin D2 by c-myc
and Wnt-1, it might be expected that a cyclin D2 knockin
would produce a similar phenotype.
Finally, Yu et al. suggest that their data provide strong evi-
dence for targeting cyclin D1 for potential therapeutic
intervention in breast cancer, particularly those with acti-
vated Neu-Ras pathways [1]. While their data are not
incompatible with such a conclusion, there are a number
of factors that suggest this is unlikely to be a priority area
in the immediate future. Several drugs are currently in
advanced preclinical and clinical development targetting
the c-erbB-2 receptor, its tyrosine kinase domain [24] and
several downstream signalling targets [25]. Furthermore,
c-erbB-2 overexpressing tumours, being predominantly
oestrogen receptor negative, are unlikely to overexpress
cyclin D1. If cyclin D1 overexpression is an early initiating
event in the development of breast cancer, however, novel
therapeutic strategies that inhibit its aberrant expression
or function may well have a role in the ultimate prevention
of a significant proportion of breast cancers. Only time
and further insightful experiments into the control of cyclin
D1 expression and function in mammary epithelium, as
reported by Sicinski and colleagues, will determine
whether patients will ultimately benefit from these impor-
tant biological advances.
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